In the neoadjuvant ICIs group, digestive and hepatic-related adverse events were largely identified, including transaminitis (ALT, AST, and gamma−glutamyltransferase), bilirubin, lipase, amylase increased, diarrhea, and colitis, which was similar to adverse events in advanced stage (39). Here, GPT is linked to colitis.